AU Patent

AU2015200149B2 — Novel antitumoral use of cabazitaxel

Assigned to Aventis Pharma SA · Expires 2016-12-01 · 9y expired

What this patent protects

The invention relates to a cabazitaxel, which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for pat…

USPTO Abstract

The invention relates to a cabazitaxel, which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

Drugs covered by this patent

Patent Metadata

Patent number
AU2015200149B2
Jurisdiction
AU
Classification
—
Expires
2016-12-01
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.